TRAF6 and acute myeloid leukemia: Augmented TLR signaling inhibition can also be achieved by combining emavusertib with a proteasome inhibitor such as bortezomib which via lysosomal degradation, can degrade the TLR-signaling intermediate TRAF6, leading to apoptosis of AML/MDS cells (92).